logo
Share SHARE
FONT-SIZE Plus   Neg

HP To Cut 850 Jobs In Germany

Hewlett-Packard Co. (HPQ) said Friday it will cut 850 jobs at its Enterprise Services business in Germany and close its site in Rüsselsheim by October, as part of a multi-year restructuring program the PC maker unraveled last May.

The closure of the Rüsselsheim site will result in the elimination of 850 positions, and those affected can apply for open positions at other HP sites. About 250 employees at the site will have the opportunity to transfer to HP partners or clients.

The Enterprise Services restructuring will not impact any of HP's other major sites in Germany, where the company has 10,000 people on its payrolls.

The necessity of job cuts in Germany stem from efficiency gains, local partner outsourcing and consolidation with its global service delivery hubs, the company said in a statement.

"...HP Enterprise Services has an aggressive plan to optimize its portfolio and its sales and delivery model, and to improve its cost structure, resource management and operations," said Mike Nefkens, executive vice president, HP Enterprise Services.

Last year, HP said it will eliminate 29,000 employees over two years in a bid to register a healthy growth trajectory. The company employs about 300,000 people worldwide.

HP is trading at $16.63, up 0.73%, on a volume of 8.2 million shares on the NYSE.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT